{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:06:31Z","timestamp":1783933591202,"version":"3.55.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>X-linked hypophosphataemia (XLH) is a rare genetic disorder characterised by defective bone and tooth mineralisation. Burosumab is a recombinant, human, anti-fibroblast growth factor 23 monoclonal antibody approved for treating XLH. Due to the rarity of the disease, additional safety data for the treatment of XLH with burosumab are required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A post-authorisation safety study analysis of data for paediatric participants from the International X-linked Hypophosphataemia Registry. This study included standard diagnostic and monitoring clinical data at participating centres, regardless of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a second interim analysis performed 5 years after study initiation in the paediatric population. Primary objectives assessed safety outcomes in children and adolescents with XLH. The secondary objective compared safety outcomes with burosumab vs phosphate and\/or active vitamin D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 340 participants were treated with \u22651 dose of burosumab, and 91 were treated with phosphate and\/or active vitamin D. Overall, 37.4% and 22.0% of participants in the burosumab or phosphate and\/or active vitamin D cohorts, respectively, experienced \u22651 adverse event. The proportions of participants with events were similar among children and adolescents. Forty-nine (14.4%) participants reported events possibly\/probably related to burosumab. No events led to the withdrawal of burosumab. In both cohorts, no serious adverse events were considered related to treatment, and there were no deaths. Hospitalisations occurred in \u223c71% of participants. Hyperphosphataemia, elevated parathyroid hormone, and ectopic mineralisation events were rare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The safety profile of burosumab was consistent with previous studies, and no new safety concerns were reported for children or adolescents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvag099","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:54:43Z","timestamp":1781870083000},"page":"10-21","source":"Crossref","is-referenced-by-count":0,"title":["Second interim analysis of the post-authorisation safety study (PASS) of burosumab in paediatric patients with X-linked hypophosphataemia"],"prefix":"10.1093","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7561-9217","authenticated-orcid":false,"given":"Signe Sparre","family":"Beck-Nielsen","sequence":"first","affiliation":[{"name":"Centre for Rare Diseases, Aarhus University Hospital , DK-8200 Aarhus ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aarhus University , DK-8200 Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1763-1098","authenticated-orcid":false,"given":"Gema","family":"Ariceta","sequence":"additional","affiliation":[{"name":"University Hospital Vall d\u2019Hebron, Autonomous University of Barcelona , 08035 Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-3222","authenticated-orcid":false,"given":"Annemieke M","family":"Boot","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen , 9713 GZ Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-0592","authenticated-orcid":false,"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[{"name":"FirmoLab, FIRMO Foundation , 50129 Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6238-2601","authenticated-orcid":false,"given":"Karine","family":"Briot","sequence":"additional","affiliation":[{"name":"AP-HP, Cochin Hospital , 75014 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4882-0425","authenticated-orcid":false,"given":"Carmen","family":"de Lucas Collantes","sequence":"additional","affiliation":[{"name":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas, Universidad Aut\u00f3noma de Madrid , 28009 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-3468","authenticated-orcid":false,"given":"Francesco","family":"Emma","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Bambino Ges\u00f9 Children's Hospital IRCCS , 00165 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-9749","authenticated-orcid":false,"given":"Sandro","family":"Giannini","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Padova , 35128 Padova ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9601-7813","authenticated-orcid":false,"given":"Dieter","family":"Haffner","sequence":"additional","affiliation":[{"name":"Department of Paediatric Kidney, Liver, Metabolic and Neurological Diseases, Hannover Medical School , 30625 Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8216-3828","authenticated-orcid":false,"given":"Richard","family":"Keen","sequence":"additional","affiliation":[{"name":"Metabolic Bone Disease Unit, Royal National Orthopaedic Hospital , Stanmore HA7 4LP ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8352-7312","authenticated-orcid":false,"given":"Elena","family":"Levtchenko","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam University Medical Centre , 1105 AZ Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9986-8138","authenticated-orcid":false,"given":"Ola","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Karolinska Institutet and University Hospital , ERN BOND, and ENDO ERN, SE-17176 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4547-001X","authenticated-orcid":false,"given":"Outi","family":"M\u00e4kitie","sequence":"additional","affiliation":[{"name":"Children's Hospital, University of Helsinki and Helsinki University Hospital , 00014 Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8603-5663","authenticated-orcid":false,"given":"M Zulf","family":"Mughal","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology, Al Jalila Children's Specialty Hospital , Dubai ,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3350-9896","authenticated-orcid":false,"given":"Raja","family":"Padidela","sequence":"additional","affiliation":[{"name":"Manchester University NHS Foundation Trust Hospital and Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester , Manchester M13 9PT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1892-7264","authenticated-orcid":false,"given":"Liana","family":"Tripto-Shkolnik","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical & Health Sciences, Tel Aviv Center , 6997801 Tel HaShomer ,","place":["Israel"]},{"name":"Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center , 52621 Tel HaShomer ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9186-3423","authenticated-orcid":false,"given":"M Carola","family":"Zillikens","sequence":"additional","affiliation":[{"name":"Erasmus MC, University Medical Center Rotterdam , 3015 GD Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El Mahdi","family":"Benchekroun","sequence":"additional","affiliation":[{"name":"Pharmacovigilance, Kyowa Kirin International Plc , 92976 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eslam","family":"Eltahan","sequence":"additional","affiliation":[{"name":"Medical Affairs, Kyowa Kirin International Plc , Dubai ,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1931-4294","authenticated-orcid":false,"given":"Paul","family":"Joos-Vandewalle","sequence":"additional","affiliation":[{"name":"Medical Affairs, Kyowa Kirin Co. Ltd. , 28046 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2011-0437","authenticated-orcid":false,"given":"Malena","family":"Melogno-Klinkas","sequence":"additional","affiliation":[{"name":"Medical Affairs, Kyowa Kirin International Plc , 28046 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7944-7790","authenticated-orcid":false,"given":"Dirk","family":"Schnabel","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology, Center for Chronically Sick Children, Charit\u00e9 Universit\u00e4tsmedizin , 13353 Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"3","key":"2026071304215658900_lvag099-B1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-08-0818","article-title":"Incidence and prevalence of nutritional and hereditary rickets in southern Denmark","volume":"160","author":"Beck-Nielsen","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026071304215658900_lvag099-B2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2026071304215658900_lvag099-B3","doi-asserted-by":"publisher","first-page":"e871","DOI":"10.1210\/clinem\/dgz203","article-title":"Prevalence and mortality of individuals with X-linked hypophosphataemia: a United Kingdom real world data analysis","volume":"105","author":"Hawley","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071304215658900_lvag099-B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116791","article-title":"Prevalence and characteristics of paediatric X-linked hypophosphataemia in Australia and New Zealand: results from the Australian and the New Zealand Paediatric Surveillance Units survey","volume":"173","author":"Sandy","year":"2023","journal-title":"Bone"},{"issue":"2","key":"2026071304215658900_lvag099-B5","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s12020-024-03793-5","article-title":"Epidemiological analysis to identify predictors of X-linked hypophosphatemia (XLH) diagnosis in an Italian pediatric population: the EPIX project","volume":"85","author":"Crisafulli","year":"2024","journal-title":"Endocrine"},{"key":"2026071304215658900_lvag099-B6","volume-title":"GeneReviews\u00ae [Internet]","author":"Laurent","year":"1993-2025"},{"issue":"5","key":"2026071304215658900_lvag099-B7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41581-024-00926-x","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"21","author":"Haffner","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"2026071304215658900_lvag099-B8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bone.2016.11.019","article-title":"Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia","volume":"95","author":"Boukpessi","year":"2017","journal-title":"Bone"},{"issue":"2","key":"2026071304215658900_lvag099-B9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/0022034517728497","article-title":"Defective mineralization in X-linked hypophosphatemia dental pulp cell cultures","volume":"97","author":"Coyac","year":"2018","journal-title":"J Dent Res"},{"issue":"8","key":"2026071304215658900_lvag099-B10","doi-asserted-by":"publisher","DOI":"10.3390\/genes13081356","article-title":"PHEXL222P mutation increases Phex expression in a new ENU mouse model for XLH disease","volume":"13","author":"El Hakam","year":"2022","journal-title":"Genes (Basel)"},{"issue":"7","key":"2026071304215658900_lvag099-B11","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician's guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026071304215658900_lvag099-B12","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1530\/EC-20-0291","article-title":"Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations","volume":"9","author":"Padidela","year":"2020","journal-title":"Endocr Connect"},{"issue":"8","key":"2026071304215658900_lvag099-B13","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1210\/jc.2003-030036","article-title":"Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets","volume":"88","author":"M\u00e4kitie","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026071304215658900_lvag099-B14","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"10189","key":"2026071304215658900_lvag099-B15","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"2026071304215658900_lvag099-B16","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/JCI72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J Clin Invest"},{"issue":"21","key":"2026071304215658900_lvag099-B17","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"2026071304215658900_lvag099-B18","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","article-title":"Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23","volume":"100","author":"Imel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026071304215658900_lvag099-B19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"2026071304215658900_lvag099-B20","doi-asserted-by":"publisher","DOI":"10.1177\/20406223241247643","article-title":"Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis","volume":"15","author":"Boot","year":"2024","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"2026071304215658900_lvag099-B21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13023-020-01434-4","article-title":"The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study","volume":"15","author":"Padidela","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"2026071304215658900_lvag099-B22","volume-title":"Summary of Product Characteristics","author":"European Medicines Agency. Crysvita","year":"2022"},{"issue":"3","key":"2026071304215658900_lvag099-B23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071304215658900_lvag099-B24","author":"European Medicines Agency"},{"key":"2026071304215658900_lvag099-B25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.947814","article-title":"Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy","volume":"13","author":"Brener","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2026071304215658900_lvag099-B26","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10672","article-title":"Burosumab and dental abscesses in children with X-linked hypophosphatemia","volume":"6","author":"Gadion","year":"2022","journal-title":"JBMR Plus"},{"issue":"5","key":"2026071304215658900_lvag099-B27","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1210\/clinem\/dgae398","article-title":"Improved oral health in adults with X-linked hypophosphatemia treated with burosumab","volume":"110","author":"Herv\u00e9","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026071304215658900_lvag099-B28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41368-023-00259-8","article-title":"Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemia","volume":"15","author":"Lira Dos Santos","year":"2023","journal-title":"Int J Oral Sci"},{"key":"2026071304215658900_lvag099-B29","doi-asserted-by":"publisher","DOI":"10.3389\/froh.2023.1087761","article-title":"Dental health of patients with X-linked hypophosphatemia: a controlled study","volume":"4","author":"Larsson","year":"2023","journal-title":"Front Oral Health"},{"issue":"1","key":"2026071304215658900_lvag099-B30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41405-024-00223-6","article-title":"Characteristics of oral health of patients with X-linked hypophosphatemia: case reports and literature review","volume":"10","author":"Arhar","year":"2024","journal-title":"BDJ Open"},{"issue":"2","key":"2026071304215658900_lvag099-B31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.57582\/IJBF.210102.074","article-title":"Dental and periodontal features and management in XLH children and adults","volume":"1","author":"Duplan","year":"2021","journal-title":"Int J Bone Frag"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvag099\/68582763\/lvag099.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/1\/10\/68582763\/lvag099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/1\/10\/68582763\/lvag099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:22:06Z","timestamp":1783930926000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/195\/1\/10\/8713673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvag099","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,23]]}}}